ASH 2022 | Ascentage Pharma to Present Initial Data of Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Combination with BTK Inhibitors for the Treatment of R/R CLL/SLL, Including an ORR of 98%, in an Oral Report at the ASH Annual Meeting.
In: PR Newswire, 2022-11-03
Zeitungsartikel
Zugriff:
Titel: |
ASH 2022 | Ascentage Pharma to Present Initial Data of Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Combination with BTK Inhibitors for the Treatment of R/R CLL/SLL, Including an ORR of 98%, in an Oral Report at the ASH Annual Meeting.
|
---|---|
Zeitschrift: | PR Newswire, 2022-11-03 |
Veröffentlichung: | 2022 |
Medientyp: | Zeitungsartikel |
Sonstiges: |
|